Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus
cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as
treatment in patients with small-cell lung cancer (SCLC) who failed one prior
platinum-containing line to determine a difference in progression-free survival (PFS) by an
Independent Review Committee (IRC) between lurbinectedin (PM01183)/doxorubicin (DOX) and the
control arm (CAV) or topotecan and to analyze the median overall survival (OS) and mid- and
long-term overall survival (OS at 12, 18 and 24 months).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society